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Abstract
The identification of better regimens in currently available chemotherapeutic agents is crucial for treating patients
with KRAS mutant metastatic colorectal cancer (mCRC). Records of mCRC patients who received first-line oxalipla-
tin-based or irinotecan-based regimens were reviewed retrospectively. Clinicopathologic features and treatment
outcome of patients with first-line progression-free survival (PFS) and overall survival (OS) in association with KRAS
mutation status were analyzed using the Cox proportional hazard model. Between 2007 and 2010, a total of 118
mCRC patients were enrolled. Among them, 67 were males and 51 were females. In patients who received first-line
oxaliplatin-based regimens, the PFS was significantly longer in KRAS mutant patients (N = 32) than that in KRAS
wild-type patients (N = 51). The median PFS was 8.5 months in KRAS mutant versus 5.8 months in KRAS wild-type
patients (P= .008). In contrast, in patients who received first-line irinotecan-based regimens, the PFS was shorter in
KRASmutant patients (N = 15) than that in KRAS wild-type patients (N = 20). Median PFS was 3.9 months in KRAS
mutant versus 6.0 months in KRAS wild-type patients (P = .23). Median OS between KRAS mutant and wild-type
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patients was not significantly different in both oxaliplatin-based and irinotecan-based regimens. In multivariate
analyses, KRAS mutation remains an independent predictive factor for longer PFS in first-line oxaliplatin-based regi-
mens. In conclusion, oxaliplatin-based chemotherapy in KRAS mutant mCRC might result in longer PFS than in
KRAS wild-type mCRC.
Translational Oncology (2013) 6, 363–369
Introduction
Mutation of theKRAS gene inmetastatic colorectal cancer (mCRC) has
been identified as a predictor of poor response to epidermal growth fac-
tor receptor (EGFR) monoclonal antibody [1]. Prospective randomized
clinical trials have further confirmed the observation [2–4]. In patients
who received first-line chemotherapy plus EGFR monoclonal anti-
bodies, progression-free survival (PFS) in KRAS mutation group was
shorter than that in KRAS wild-type group, with 7.6 versus 9.9 months
in the CRYSTAL study [2], 5.5 versus 7.7 months in the OPUS study
[3], and 7.3 versus 9.6 months in the PRIME [4] study. On the basis of
the results of these studies, mCRC patients with mutant KRAS have no
longer been suggested to use EGFR monoclonal antibody. Thereafter,
KRAS mutant mCRC patients have fewer treatment options than
KRAS wild-type patients. To identify better regimens from currently
available systemic treatments or exploration of newer agents for the
treatment of KRAS mutant mCRC patients is thus warranted.
If we primarily focus on chemotherapy alone group in the OPUS
and PRIME studies, in which first-line oxaliplatin-based chemotherapy
(FOLFOX, oxaliplatin/5-fluorouracil (5-FU)/leucovorin) was given in
both studies, it is intriguing to find that the PFS in KRAS mutant
group was longer than the PFS in KRAS wild-type group, with 8.6
versus 7.2 months in the OPUS study [3] and 8.8 versus 8.0 months
in the PRIME study [4]. In contrast, in the CRYSTAL study [2], if we
focused on chemotherapy alone group, in which first-line irinotecan-
based chemotherapy (FOLFIRI, irinotecan/5-FU/leucovorin) was given,
the median PFS was 7.7 months in KRASmutant group and 8.4 months
in the KRAS wild-type group.
According to these observations, we hypothesized that KRASmutant
mCRC patients might have longer PFS during first-line oxaliplatin-
based chemotherapy than patients with wild-type KRAS. We retrospec-
tively collected clinical data from mCRC patients who had received
first-line oxaliplatin-based or irinotecan-based regimens. We also deter-
mined the KRAS mutation status of these patients to compare differ-
ences in PFS during first-line chemotherapy and overall survival (OS)
between the KRAS mutant and wild-type groups for both chemother-
apy regimens. Univariate and multivariate analyses were performed in
patients with first-line oxaliplatin-based or irinotecan-based regimens to
identify potential biomarkers for PFS during first-line chemotherapy
and OS.
Materials and Methods
Patient Eligibility
Between 2007 and 2010, lists of patients diagnosed with CRC of any
stage were obtained from Medical Information Management Office
and the Cancer Registry Office of National Taiwan University Hospital
(NTUH). Study subjects were further identified by the following inclu-
sion criteria. Patients were eligible if 1) their diseases had recurred to
becomemetastatic after an initial diagnosis of stage I to III CRC; 2) they
were initially diagnosed as stage IV diseases; 3) they were older than
18 years of age; 4) they had received first-line oxaliplatin-based regimens
(oxaliplatin/5-FU/leucovorin or oxaliplatin/capecitabine) or irinotecan-
based regimens (irinotecan/5-FU/leucovorin or irinotecan/capecitabine);
5) they had adequate archival tumor samples for KRAS mutation analy-
sis; 6) they had signed informed consent; 7) they had complete medical
chart record and regular computed tomography (CT) scan follow-up
reports. Patients were excluded if they 1) had resectablemetastatic disease
and immediately received complete resection of all tumors after the
diagnosis (R0 resection); 2) they had received molecular targeted ther-
apy (bevacizumab or cetuximab) in their first-line treatment; 3) they
had multiple cancers; 4) they had active uncontrolled infection; 5) they
had human immunodeficiency virus infection; 6) they had poorly
controlled heart failure (New York Heart Association class IV). All
patients were treated at NTUH, and the data for analysis were locked
in December 2011. This study was approved by the Institutional Review
Board of NTUH. Detailed information collected for analysis included
1) age at diagnosis, 2) sex, 3) pathology reports, 4) date that patients
were diagnosed with CRC of any stage, 5) date of disease recurrence to
become stage IV for those patients initially diagnosed as having stage I
to III disease, 6) location of primary CRC, 7) sites of metastases,
8) initiation date of first-line oxaliplatin-based or irinotecan-based regi-
mens, 9) date of first-line progression, and 10) date of death.
Diagnosis
Diagnosis of CRC was confirmed by reviewing the morphology of
cancer cells and immunohistochemistry (CK20 or CDX2) of patho-
logic specimens by two independent pathologists. Disease extent was
routinely determined by CT of the chest, abdomen, and pelvis as
well as bone scans if bone metastasis was suspected. Positron emission
tomography/CT scan was performed to identify potentially curable
patients or to clarify suspected lesions to determine the clinical stage.
The KRAS gene mutation test was performed by professionals at the
pathology department in NTUH.
Treatment
For patients who met all inclusion and exclusion criteria, their
treatments were determined mainly by appropriate treatment goals,
which were administered either with potentially curative intent or for
palliative purposes. Figure 1 summarized all the multidisciplinary
treatment that patients had received in the current study.
Patients, in whom the intent was potentially curative, with border-
line resectable cancers, were treated with neoadjuvant chemotherapy,
followed by surgery if applicable. In subsequent chemotherapy, either
for patients whose tumors had been resected or for those whose
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tumors remained unresectable, the same regimens were continued
until the disease progressed or toxicity levels became intolerable.
Patients with widely spread metastatic disease who were treated for
palliative purposes received systemic chemotherapy until the disease
progressed or became suitable for local therapy with either radio-
frequency ablation, transarterial embolization, or metastasectomy. All
systemic treatments were determined by treating physicians according
to patients’ performance status, age, and comorbidities.
Efficacy Assessment
The PFS during first-line chemotherapy and OS were compared
between patients with KRAS mutation and those with KRAS wild
type for both oxaliplatin-based and irinotecan-based regimens. The
PFS during first-line chemotherapy was determined from the first
day of first-line chemotherapy to the first-line progression as docu-
mented by either CT scan, positron emission tomography/CT scan,
bone scan, or death. For those with borderline resectable cancers,
whose tumors could be completely resected after neoadjuvant chemo-
therapy, the PFS during first-line chemotherapy was counted from the
first day of chemotherapy to the date of surgery. These patients were
recorded as censored at the date of surgery. For the rest of the patients
with borderline resectable cancers, whose tumors remained unresect-
able after neoadjuvant chemotherapy, the PFS during first-line chemo-
therapy was counted from the first day of chemotherapy to the date of
progression during first-line chemotherapy.
For patients with widely spread metastatic diseases, the PFS during
first-line chemotherapy was counted from the first day of chemother-
apy until the date of first-line chemotherapy progression or until the
date of local therapy, including radiofrequency ablation, transarterial
embolization, or metastasectomy, during which there was no evidence
of progression within the period of first-line chemotherapy treatment.
The patients were recorded as censored at the date of local therapy.
OS was calculated from the date diagnosed as stage IV CRC to the
date of death or the last visit with censoring. Patients who had not
died at the time of analysis were recorded as censored at the time
they were last known to be alive. A final analysis of the OS was per-
formed when 65% of the study patients died.
Assessment
Tumor assessments were routinely performed by CT scan of the
chest/abdomen/pelvis and by bone scan if bone metastasis was sus-
pected at the time of diagnosis (baseline), as well as every 3 months
thereafter if disease status was under control. Once the disease progres-
sion was suspected, any diagnostic tools indicated for confirmation of
the progression would be performed within the 3-month interval.
Assay to Detect Mutant KRAS
Mutation analysis of KRAS was performed by extraction of genomic
DNA from formalin-fixed, paraffin-embedded tissue slides or sections.
For KRAS analyses, the following primer sets for exon 2 were used:
huKRAS2 ex2F, 5′GAATGGTCCTGCACCAGTAA3′; huKRAS2
ex2R, 5′GTGTGACATGTTCTAATATAGTCA3′. Genomic DNA
was amplified using a primer pair; the length of the polymerase chain
reaction (PCR) product was 220 bp. The PCR mixture contained 5 μl
of 2×HotStarTaqMasterMix containingHotStarTaqDNAPolymerase
(Qiagen, Hilden, Germany), PCR buffer, and deoxyribonucleotide tri-
phosphates (dNTPs), 10 pmol of each primer, and 2 μl of genomic
DNA (20 ng) in a final volume of 10 μl. Conditions for PCR carried
out in the thermal cycler (Biometra TProfessional Basic) were given as
follows: 1 cycle at 94°C for 15 minutes; 45 cycles at 94°C for 30 sec-
onds, 57°C for 30 seconds, and 72°C for 30 seconds; followed by 1 cycle
at 72°C for 7 minutes. Purification of the amplified product was then
performed using the Geneaid Gel/PCR DNA Fragments Extraction
Kit. The sequence of the purified amplification product (60 ng) was
analyzed using an Applied Biosystems 3730DNAAnalyzer.
Statistical Analysis
We hypothesized that the first-line progression-free percentage in
KRAS mutant and wild-type patients receiving oxaliplatin-based regi-
mens at 12-month period would be 35% and 10%, respectively. A
total of estimated 82 patients receiving oxaliplatin-based regimens
would be needed to detect the potential of 25% difference, with a
power of 80%, at the significance level of .05 (one-sided test). The
Kaplan-Meier method was used to estimate the PFS during first-line
chemotherapy and OS. The log-rank test was used for univariate
comparisons, and the Cox proportional hazard model was used to
identify potential biomarkers for PFS during first-line chemotherapy
and OS. A P value < .05 was used to indicate statistical significance;
all tests except sample size calculation were two-sided. These analyses
were performed using SPSS version 16.0 for Windows.
Results
Patient Population
Between 2007 and 2010, 466 patients who received appropriate
treatment were identified as stage I to IV CRC. Of these, 118 patients
were eligible to analyze in the current study by inclusion and exclu-
sion criteria. The selected patients (N = 118) were further stratified by
oxaliplatin-based and irinotecan-based regimens as well as KRAS
mutation status. A flowchart of the patients in each group is shown
in Figure 2. Among those who received oxaliplatin-based regimens,
four patients in KRAS mutant group and four patients in KRAS
wild-type group had curative surgery after neoadjuvant chemotherapy.
Figure 1. Treatment flowchart of all the multidisciplinary treatment
options that patients had received.
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However, among those who received irinotecan-based regimens, none
in KRAS mutant group while only one in KRAS wild-type group had
curative surgery after neoadjuvant chemotherapy. Table 1 summarizes
the baseline patient characteristics.
Treatment Outcomes
In patients who received first-line oxaliplatin-based regimens, the PFS
in KRAS mutant group (N = 32) was significantly longer than that in
KRAS wild-type group (N = 51). The PFS was 8.5 months [95% con-
fidence interval (CI): 5.5–11.5] inKRASmutant group and 5.8 months
(95% CI: 5.1–6.5) in KRAS wild-type group (P = .008; Figure 3A); in
contrast, for patients who received first-line irinotecan-based regi-
mens, the PFS was 3.9 months (95% CI: 3.3–4.5) in KRAS mutant
group (N = 15) and 6.0 months (95% CI: 4.8–7.3) in KRAS wild-type
group (N = 20). The difference of PFS between KRASmutant and wild
type was not significantly different (P = .23; Figure 3B).
Comparison of the KRASmutation and wild-type groups with respect
to the outcome of OS revealed that the difference of OS in neither
oxaliplatin-based nor irinotecan-based regimens was statistically signifi-
cantly different between the groups. In patients who received first-line
oxaliplatin-based regimens, the median OS was 25.6 months (95% CI:
12.7–38.5) inKRASmutation group (N = 32) and 23.8 months (95%CI:
14.6–32.9) in KRASwild-type group (N = 51, P = .92; Figure 3C ). In ad-
dition, in patients who received first-line irinotecan-based regimens,
OS was 19.0 months (95% CI: 3.8–34.2) in KRAS mutant group
(N = 15) and 28.9 months (95% CI: 21.4–36.4) in KRAS wild-type
(N = 20) group (P = .69; Figure 3D).
Furthermore, when we excluded patients who received curative
surgery after neoadjuvant chemotherapy for OS analysis, we found that
the difference of OS between KRAS mutant and wild-type groups in
either oxaliplatin-based or irinotecan-based regimens remained not
statistically significant. For patients who received oxaliplatin-based regi-
mens, OS was 22.8 (95% CI: 18.2–27.4) months in KRAS mutant
and 20.9 (95% CI: 14.1–27.7) months in KRAS wild-type patients
(P = .9). For patients who received irinotecan-based regimens, OS was
19.0 (95% CI: 3.8–34.2) months in KRAS mutant patients and 27.2
(95% CI: 21.1–33.3) months in KRAS wild-type patients (P = .79).
Univariate and Multivariate Analyses
The Cox proportional hazard model was further used to test other
potential confounding factors that might influence PFS during first-
line chemotherapy or OS in patients with oxaliplatin-based or irinotecan-
based regimens. The factors includedwere age (≤50 vs >50), sex (female vs
male), initial stage of the disease (stages I to III vs stage IV), location of
the tumor (distal vs proximal), and number of metastases (1 vs 2 vs≥3).
In summary, in patients who received first-line oxaliplatin-based regi-
mens, the KRASmutation was an independent predictive factor for lon-
ger PFS, which was demonstrated not only in univariate but also in
multivariate analyses. Female gender and metastases in more than
two sites were, in contrast, independent predictive and prognostic fac-
tors for shorter PFS and OS, respectively (Tables 2 and 3). In patients
who received first-line irinotecan-based regimens, no factors were found
to be independently predictive or prognostic for PFS during first-line
chemotherapy or OS (Tables 2 and 3).
Discussion
Our study reveals that KRAS mutant mCRC patients might have
longer PFS during first-line oxaliplatin-based chemotherapy than
KRAS wild-type patients. This finding might be an important step
toward personalized chemotherapy for mCRC.
In the era before targeted therapy, Tournigand et al. [5] published
a pivotal article reporting that first-line chemotherapy with either
irinotecan/5-FU/lecovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin
(FOLFOX6) in “nonselected” mCRC patients did not influence OS.
Both regimens could thus be recommended as first-line treatment for
mCRC. In the modern era of targeted therapy, current treatment for
Table 1. Patient and Disease Characteristics at Baseline.
Characteristics Overall
(N = 118)
Oxaliplatin-Based
(N = 83)
Irinotecan-Based
(N = 35)
No. of Patients % No. of Patients % No. of Patients %
Sex
Male 67 57 45 54 22 63
Female 51 43 38 46 13 37
Age, years
Median 61 60 64
Range 15–86 15–86 25–81
>50 96 81 66 80 30 86
≤50 22 19 17 20 5 14
KRAS
Wild type 72 61 52 63 20 57
Mutant 46 39 31 37 15 43
Tumor site
Proximal* 34 29 27 33 7 20
Distal† 84 71 56 67 28 80
No. of metastatic sites
1 67 57 50 60 17 49
2 41 35 27 33 14 40
≥3 10 8 6 7 4 11
Initial stage
I–III 38 32 19 23 19 54
IV 80 68 64 77 16 46
*Proximal indicates cecum, ascending colon, hepatic flexure, and transverse colon.
†Distal indicates splenic flexure, descending colon, sigmoid colon, and rectum.
Figure 2. Disposition of subjects at the timeof data cutoff and analysis.
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mCRC has been advanced to personalized therapy after mutant KRAS
was identified as a predictor for unresponsiveness to EGFRmonoclonal
antibody. Currently, KRASmutation status has been routinely checked
in daily oncology practice to avoid inappropriate use of EGFR mono-
clonal antibody in KRAS mutant mCRC patients. As KRAS mutant
mCRC patients has fewer treatments currently, to identify better regi-
mens in current chemotherapy or newer treatment targets for the approx-
imately 40% of KRAS mutant mCRC patients [6–9] is warranted.
Figure 3. (A) First-line PFS stratified by KRAS mutational status in patients with first-line oxaliplatin-based regimens. (B) First-line PFS
stratified by KRAS mutational status in patients with first-line irinotecan-based regimens. (C) OS stratified by KRAS mutational status
in patients with first-line oxaliplatin-based regimens. (D) OS stratified by KRAS mutational status in patients with first-line irinotecan-
based regimens.
Table 2. Cox Proportional Hazard Model for PFS in Patients Treated with Irinotecan-Based and Oxaliplatin-Based Regimens.
Variable Irinotecan-Based Regimens (N = 35) Oxaliplatin-Based Regimens (N = 83)
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR* 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age 1.00 .74 .86 .48
≤50 1.00 1.00 1.00 0.51–1.75 1.00
>50 1.00 0.37–2.74 1.22 0.38–3.97 0.95 0.78 0.39–1.55
Sex .36 .45 .13 .01
Female 1.00 1.00 1.00 1.00
Male 0.69 0.31–1.53 0.66 0.22–1.96 0.68 0.42–1.12 0.46 0.26–0.82
KRAS .22 .32 .008 .003
Mutant 1.00 1.00 1.00 1.00
Wild type 0.61 0.28–1.34 0.61 0.23–1.60 2.09 1.21–3.62 2.46 1.37–4.43
Initial diagnosis as stage IV .30 .44 .23 .13
No 1.00 1.00 1.00 1.00
Yes 0.65 0.29–1.46 0.67 0.25–1.83 1.44 0.79–2.62 1.68 0.85–3.31
Tumor site .72 .92 .94 .33
Distal 1.00 1.00 1.00 1.00
Proximal 1.19 0.46–3.07 0.95 0.33–2.72 0.98 0.58–1.65 0.71 0.36–1.41
No. of metastatic sites
1 1.00 1.00 1.00 1.00
2 0.83 0.35–1.93 .66 0.87 0.25–3.05 .83 1.28 0.76–2.17 .36 1.45 0.81–2.59 .21
≥3 1.88 0.40–8.91 .43 1.97 0.39–10.00 .41 4.28 1.61–11.37 .004 3.87 1.28–11.68 .02
*HR, hazard ratio.
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Our study was initiated to validate better regimens in current chemo-
therapy. The hypothesis that KRASmutant mCRC patients might have
longer PFS during first-line oxaliplatin-based chemotherapy than KRAS
wild-type patients was generated from subgroup analyses of randomized
prospective clinical trials, PRIME [4] and OPUS [3] versus CRYSTAL
[2]. Although our sample size is limited, our study demonstrated again
that KRASmutant mCRC patients might have longer PFS during first-
line oxaliplatin-based chemotherapy than KRAS wild-type patients.
Our finding is compatible to that in the subgroup analyses of the pro-
spective, randomized PRIME and OPUS studies. Although this obser-
vation may warrant further confirmation by large prospective clinical
trials, however, after entering the targeted therapy era, it is hard to con-
duct this kind of study without incorporating targeted therapy, bevaci-
zumab or cetuximab, into the first-line setting. Our patient cohort was
treated during 2007 and 2010. During that period of time, targeted
agents, bevacizumab and cetuximab, had not been reimbursed in the
first-line setting by the National Health Insurance System in Taiwan.
Thus, this is a highly valuable data set to evaluate the impact of KRAS
status on solely first-line chemotherapy without adding targeted agents.
For this reason, it further pointed out the value of the current study
toward personalized chemotherapy.
To further support our hypothesis that KRASmutant mCRC patients
might benefit more from oxaliplatin-based regimens, we recently
completed an in vitro study [10] showing that KRASmutation is a pre-
dictor of oxaliplatin sensitivity in colon cancer cells. In our in vitro
study, KRAS gene was knocked down in KRAS mutant CRC cells
(DLD-1G13D and SW480G12V) by small interfering RNA and over-
expressed in KRAS wild-type CRC cells (COLO320DM) by KRAS
mutant vectors to generate paired CRC cells for the experiments. We
clearly demonstrated that KRAS mutant CRC cells are more sensitive
to oxaliplatin than KRAS wild-type CRC cells by the mechanism of
excision repair cross-complementation group 1 (ERCC1) down-
regulation. This in vitro finding further strengthened our results in the
current study.
Personalized chemotherapy is important, if achievable, although we
currently are in the era of molecular targeted therapy. Chemotherapy
remains the backbone of the treatment for all mCRC patients. Every
cancer patient may benefit from personalized chemotherapy if we can
find robust and meaningful biomarkers. Our study demonstrated that
determining the mutation status of the KRAS gene is not only essen-
tial for selecting the treatment of EGFR monoclonal antibody appro-
priately but also for personalizing current chemotherapeutic agents for
patients with mCRC. Several biomarkers have been identified for the
use in determining the efficacy of chemotherapy for colon cancers,
including ERCC1 expression to predict resistance to oxaliplatin [11]
and thymidylate synthase expression to determine the sensitivity of
5-FU [12]. However, tests for most of these biomarkers are not checked
as extensively and routinely as the KRAS mutational status due to dif-
ferences in the reliability of test results. ERCC1 and thymidylate
synthase expression are determined using immunohistochemistry, the
results of which are subjected to subjectively semi-quantitative inter-
pretation. In contrast, the KRAS mutation status is determined by
direct sequencing of tumor DNA, which yields more accurate results.
KRAS mutant mCRC patients might have longer PFS during first-line
oxaliplatin-based regimens than KRAS wild-type patients. Although the
detailed mechanism underlying this observation remains elusive, cross
talks between the mutated KRAS gene and DNA repair machinery
pathways, which might be responsible for the effect of oxaliplatin-based
treatment, have been investigated [13,14]. This novel finding might
result in a potential paradigm shift in the current standard treatment
for KRAS mutant mCRC.
Multivariate analysis in the present study revealed that female
gender and metastases in more than two sites were independent pre-
dictive and prognostic factors for shorter PFS and OS in patients
undergoing first-line oxaliplatin-based therapy. The fact that patients
with more than two metastatic sites predicted worse outcomes may
demonstrate the quality and accuracy of the data, but the reason that
female gender is a biomarker of poorer treatment outcome remains
elusive. Confirmation of the associations between gender and the
KRAS mutation by further studies may be warranted.
Our study did have limitations. First, it was conducted retrospec-
tively with a relatively small sample size. A further larger, prospective
Table 3. Cox Proportional Hazard Model for OS in Patients Treated by Irinotecan-Based and Oxaliplatin-Based Regimens.
Variable Irinotecan-Based Regimens (N = 35) Oxaliplatin-Based Regimens (N = 83)
Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis
HR* 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Age .91 .91 .21 .83
≤50 1.00 1.00 1.00 1.00
>50 0.92 0.21–4.06 0.91 0.17–4.78 0.66 0.35–1.27 0.92 0.43–1.98
Sex .47 .43 .04 .01
Female 1.00 1.00 1.00 1.00
Male 1.44 0.53–3.87 1.6 0.49–5.19 0.56 0.32–0.98 0.42 0.22–0.78
KRAS .69 .71 .94 .90
Mutant 1.00 1.00 1.00 1.00
Wild type 0.82 0.32–2.15 0.83 0.3–2.26 0.98 0.56–1.70 1.04 0.56–1.94
Initial diagnosis as stage IV .49 .45 .14 .16
No 1.00 1.00 1.00 1.00
Yes 1.41 0.53–3.80 1.52 0.51–4.56 1.69 0.85–3.39 1.77 0.81–3.87
Tumor site .66 .87 .45 .40
Distal 1.00 1.00 1.00 1.00
Proximal 0.75 0.21–2.64 0.88 0.19–4.01 1.26 0.70–2.29 0.74 0.37–1.49
No. of metastatic sites
1 1.00 1.00 1.00 1.00
2 0.89 0.31–2.60 .83 0.70 0.22–2.26 .55 2.02 1.13–3.6 .02 2.03 1.12–3.69 .02
≥3 2.00 0.53–7.60 .31 1.98 0.48–8.14 .34 9.82 3.4–28.38 <.001 8.22 2.45–27.6 .001
*HR, hazard ratio.
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study is warranted to confirm our results. However, as we mentioned
earlier, it is hard to conduct this kind of study without incorporating
targeted therapy, bevacizumab or cetuximab, into the first-line setting,
especially when bevacizumab has been reimbursed by the National
Health Insurance System in Taiwan since June 2011. Second, although
selection bias is hardly avoided in a retrospective study just like ours, we
do not think there were major impacts of patient selection on OS in our
study, because OS between first-line oxaliplatin-based and irinotecan-
based groups was not significantly different (P = .91) in our study,
which was compatible to those reported by Tournigand et al. [5].
Third, our study was not powered to determine whether different
KRAS mutant subtypes would give the same results as the current
study. Different KRASmutant subtypes may have different biologic be-
haviors with different treatment outcomes, as reported in several studies
[15,16]. This question also warrants further clinical study with more
patients to answer.
In conclusion, our data suggest that oxaliplatin-based chemotherapy
might provide longer PFS in KRAS mutant mCRC than in KRAS
wild-type mCRC.
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